Butabarbital
An intermediate-acting barbiturate used historically as a sedative and hypnotic for insomnia and anxiety. It acts by enhancing GABA-A receptor activity to produce sedation and sleep. It has largely been replaced by benzodiazepines and other hypnotics due to a narrower safety margin and higher abuse potential.
Peso Molecular
212,2500 g/mol
LogP
1,60
TPSA
75,30 Ų
Regra dos 5 de Lipinski
Aprovado
Mecanismo de Ação
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CCC(C)C1(CC)C(=O)NC(=O)NC1=O
InChI
InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
Molecular Formula
C10H16N2O3
HBD / HBA
2 / 3
Ligações Rotacionáveis
3
Átomos Pesados
15
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
An intermediate-acting barbiturate used historically as a sedative and hypnotic for insomnia and anxiety. It acts by enhancing GABA-A receptor activity to produce sedation and sleep. It has largely been replaced by benzodiazepines and other hypnotics due to a narrower safety margin and higher abuse potential.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Butabarbital is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL449. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2479. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="butabarbital"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/butabarbital/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/butabarbital/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/butabarbital/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="butabarbital"></drugfyi-drug>